Chugai Plans Japan Launch Of Combo Breast-Cancer Drug In 2013
This article was originally published in PharmAsia News
Chugai Pharmaceutical says it expects to apply for Japan approval next year for its T-DMI1 (trasfuzumab/emtansine) antibody drug conjugate for HER2-positive breast cancer.
You may also be interested in...
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Becton Dickinson will spend $1.2bn over the next four years to improve its drug-delivery device manufacturing capabilities. See what Eric Borin, president of BD, said about it here.
Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.